Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,833 Cr.
- Current Price ₹ 174
- High / Low ₹ 191 / 105
- Stock P/E 17.2
- Book Value ₹ 99.7
- Dividend Yield 0.29 %
- ROCE 11.7 %
- ROE 8.36 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 3.27% over past five years.
- Company has a low return on equity of 8.95% over last 3 years.
- Earnings include an other income of Rs.67.8 Cr.
- Company has high debtors of 198 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 834 | |
273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 700 | |
Operating Profit | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 134 |
OPM % | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 16% |
28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 68 | |
Interest | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 |
Depreciation | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 31 |
Profit before tax | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 159 |
Tax % | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | |
41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 112 | |
EPS in Rs | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 10.12 |
Dividend Payout % | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 3% |
3 Years: | 3% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 3% |
5 Years: | -4% |
3 Years: | 44% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | -1% |
5 Years: | 10% |
3 Years: | 31% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
Reserves | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 |
173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | |
123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 162 | |
Total Liabilities | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | |
CWIP | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 |
365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 870 | |
Total Assets | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | |
-11 | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 | |
-8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | |
Net Cash Flow | 22 | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 |
Inventory Days | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 |
Days Payable | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 |
Cash Conversion Cycle | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 |
Working Capital Days | 86 | 105 | 84 | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 199 |
ROCE % | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% |
Documents
Announcements
-
Proceedings Of 40Th Annual General Meeting Of Bliss GVS Pharma Limited
22h - 40th AGM held; final dividend 50%; operational updates; director re-appointment; secretarial auditor appointed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24h - Copies of the Newspaper Publication regarding the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.
-
Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019
2d - Granted 268,000 stock options at Rs.43 each under 2019 ESOP plan with 4-year vesting schedule.
- Outcome Of Board Meeting Held On Tuesday, July 29, 2025 2d
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, July 29, 2025
2d - Approved Q1 FY2026 unaudited standalone and consolidated financial results with auditor review.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. [1] [2]